Skip to main content
OpenTrials
Completed

NCT Number: NCT01046643

Early Menopause Hormone Treatment and Cognition

The objective of this study is to evaluate the neurobiological effects of hormone therapy (HT) in healthy early postmenopausal women. The studies proposed in this project seek to define the association between different hormone forms (estradiol only and progesterone only) versus placebo on brain functional measures. The functional measures will include the performance of the volunteers on a comprehensive neuropsychological testing battery, and the brain functional responses to episodic memory (verbal and non-verbal) challenges as well as emotional processing determined with functional magnetic resonance imaging (fMRI).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Menopausal Syndrome

Age range

45 year–55 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

The University of Michigan

Ann Arbor, Michigan, 48109, United States

About this study

Specific Aims

Aim 1. To examine the effects of estradiol alone on brain functioning in early post-menopausal women during verbal and non-verbal cognitive tasks.

Hypothesis: It is expected that with estradiol treatment brain activation will be more prominent in the hippocampus and prefrontal cortical areas compared to placebo. The magnitude of activation in these regions will be positively correlated with task performance in the scanner and with the results of neuropsychological tests assessing verbal and non-verbal delayed recall.

Aim 2. To determine the effects of progesterone alone on brain functioning in early postmenopausal women during verbal and non-verbal cognitive tasks.

Hypothesis: It is expected that with progesterone treatment brain activation in the hippocampus and prefrontal cortical areas will be decreased compared to both the placebo condition (within subjects) and the estradiol condition (between subjects). Interindividual variations in the magnitude of activation in these regions will be positively correlated with task performance in the scanner and with the results of neuropsychological tests assessing verbal and non-verbal delayed recall.

Aim 3. To determine the individual effects of estradiol and progesterone on brain functioning in early postmenopausal women during emotional processing stimuli.

Hypothesis: During negative stimuli estradiol-treated women compared to placebo group, are expected to have increased activity in the amygdala, posterior cingulate, and orbitofrontal cortex, while in progesterone-treated women compared to placebo, decreased activity is expected in these brain regions.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Postmenopausal women
  • Ages 45-55, 6 - 36 months from their last menstrual period.

Exclusion criteria

  • Left handedness
  • Acute medical illness
  • Neurologic illness
  • Psychiatric illness
  • Heart disease
  • Thromboembolic disease
  • Liver disease
  • Uncorrected thyroid disease
  • Diabetes
  • Neurological disease
  • Porphyria
  • Allergy to estradiol
  • Progesterone or lactose
  • Lactose intolerance
  • Claustrophobia
  • Contraindications to MRI (including pacemakers, surgical clips or metallic surgical devices)
  • Smoking within the last 3 years
  • Use of hormones within the last 3 months
  • Current or past history of substance abuse
  • History of head injury or loss of consciousness
  • Medications with actions on the central nervous system
  • Endometrial lining greater than 5mm
  • Ovarian pathology on ultrasound
  • Abnormal mammogram
  • Migraines
  • Fasting cholesterol >300 mg/dl, and fasting triglycerides >300 mg/dl
  • Creatinine level > 1.5 mg/dl
  • Aspartate transaminase (AST) or Alanine transaminase (ALT) greater than two times the top normal range
  • Follicle stimulating hormone (FSH) values <40 IU/L
  • estradiol >40 pg/ml.
  • Subjects with HAM-D score > 8, HAM-A > 6 during screening will not be eligible.

Treatment and study plan

Estradiol (E2)

Drug

One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days; followed by one Progesterone (200mg) once a day, at the same time each day, for 10 days to slough endometrial lining; followed by one Placebo capsule once a day, at the same time each day, for 90 days.

Other names: E2

Progesterone (P10) x90

Drug

One Progesterone capsule (200mg) once a day, at the same time each day, for 90 days; followed by one Placebo capsule (to mirror Progesterone capsule to slough endometrial lining in Estradiol recipients) once a day, at the same time each day, for 10 days ; followed by one Placebo capsule once a day, at the same time each day, for 90 days.

Other names: P10

Progesterone (P10) x10

Drug

One Progesterone (200mg) capsule once a day for 10 days, to slough endometrial lining for patients taking Estradiol. Patients taking Progesterone will take an equivalent Placebo capsule during this time period.

Other names: P10

Primary outcomes

  1. Changes in Brain Activation Patterns in Verbal Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans

    Time frame: August 2010 - March 2012

    Measure the changes in brain activity in verbal tasks with hormone use (either estradiol or progesterone) versus placebo.

    The test is a deep and shallow verbal processing task, where the subjects are presented lists of words, one word at a time, and are asked to make one of 2 decisions about each list. One decision is whether each word is written in upper or lower case letters (shallow processing), and the other decision is whether each word denotes an abstract or concrete concept (deep processing).

    The test was administered 3 months after baseline and 38 weeks after baseline.

  2. Changes in Brain Activation Patterns in Visual Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans

    Time frame: August 2010 - March 2012

    Measure the changes in brain activity in visual tasks with hormone use (either estradiol or progesterone) versus placebo.

    The test is a visual working memory task, where the women are presented with 3 geometric grids on the screen. The target grid is on top, and 2 test grids are on the bottom. The women must decide if the right or left test grid matches the grid on top. There are 3 conditions: a match condition where all 3 grids are shown simultaneously, and 2 delay conditions, where the target grid is shown first, disappears, and the test grids appear after a 1 or a 4 second delay.

    The test was administered 3 months after baseline and 38 weeks after baseline.

Secondary outcomes

  1. Neuropsychological Testing Scores - Verbal Learning Retention

    Time frame: August 2010 - March 2012

    Changes in neuropsychological testing measures (verbal learning retention) with hormone use (either estradiol or progesterone) versus placebo.

    Subjects are given tests that present them with a series of words. They are asked to recall how many items they can remember, and then some time later, are asked to recall the items again. The retention measure is how many items they can remember at the later time point, compared to the earlier time point. Adapted from the Benton Visual Memory Test, Revised.

    The tests were administered 3 months after baseline and 38 weeks after baseline.

  2. Neuropsychological Testing Scores - Visual Learning Retention

    Time frame: August 2010 - March 2012

    Changes in neuropsychological testing measures (visual learning retention) with hormone use (either estradiol or progesterone) versus placebo.

    Subjects are given tests that present them with a series of pictures. They are asked to recall how many items they can remember, and then some time later, are asked to recall the items again. The retention measure is how many items they can remember at the later time point, compared to the earlier time point. Adapted from the California Verbal Learning Test - 2nd edition.

    The tests were administered 3 months after baseline and 38 weeks after baseline.

Sponsors and collaborators

Lead sponsor

University of Michigan

Other

Collaborators

  • National Institute on Aging (NIA)

Registry information

Official study title

Hormones and Cognitive Processing in Early Postmenopausal Women

Acronym: R21

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Jan 12, 2010
Registry last updated
May 19, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.